February 20, 2026 — Leads & Copy — Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE) plans to hire over 700 scientific, technical, and management professionals during 2026–27. The expansion will scale capabilities to meet growing global demand for end-to-end drug discovery, development, and manufacturing services.
The recruitment will span roles across medicinal chemistry, biology, DMPK, process and analytical development, formulation development, process engineering, technology transfer, quality, peptides, business development, program management, and manufacturing.
A specific area of focus through this recruitment drive will be on attracting high-calibre scientists from leading institutions in India and globally. The company says this reflects the increasing complexity of programs being entrusted to Sai Life Sciences and the higher scientific expectations placed on Indian CRDMOs by global innovator companies.
According to Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, the Indian CRDMO industry is at an inflection point. Kanumuri said that global supply-chain rebalancing, the need for resilient development and manufacturing partners, and the rising sophistication of outsourced science are converging in India’s favour. He added that demand for high-quality, integrated partners is already visible, and this expansion is about preparing to serve that demand at scale with the right infrastructure, digital and quality systems, and scientific capability.
Kanumuri said that this is an exciting moment for scientists, who now have the opportunity to work on globally relevant, high-impact programs while being based in India. He believes this phase of growth creates a compelling opportunity for Indian scientists anywhere in the world to consider building the next chapter of their careers in India, without compromising on scientific rigor, exposure, or the quality of work.
The new roles will support growing activity in areas such as complex small-molecule synthesis, high-throughput experimentation, data-enabled drug discovery, and late-stage CMC and commercial manufacturing scale-up.
As part of its talent strategy, Sai Life Sciences has launched a global alumni engagement platform and is strengthening learning, leadership development, and internal mobility programs to support long-term career growth.
Sai Life Sciences operates across India, the UK, and the US, serving global pharmaceutical and biotechnology companies. Its Manchester site focuses on process R&D, while its Boston Biology facility supports early discovery collaborations and client engagement. The majority of new roles will be based in Hyderabad, home to the company’s largest integrated R&D campus. Sai Life Sciences currently has more than 3,400 scientists and professionals on board.
Sai Life Sciences is a full-service CRDMO working with innovator pharma and biotech companies globally to accelerate the discovery, development, and commercialization of small molecules. With operations across India, the UK, and the US, Sai Life Sciences offers scientific expertise, world-class infrastructure, and a culture of excellence focused on quality, safety, and sustainability.
Source: Sai Life Sciences
